Research Citations & Studies
Comprehensive collection of peer-reviewed scientific studies, clinical trials, and research publications examining Ivermectin's therapeutic mechanisms, safety profile, and clinical applications. All citations include DOI and PubMed identifiers for verification.
About This Research Database
This page aggregates peer-reviewed scientific research from reputable medical journals for educational purposes. Each citation includes complete bibliographic information, DOI (Digital Object Identifier), and PubMed ID (PMID) for independent verification.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. Always consult qualified healthcare professionals before making treatment decisions.
Peer-Reviewed Scientific Evidence
Every study cited includes DOI and PubMed verification for complete transparency
Anti-Inflammatory Research
4 peer-reviewed studies
Anti-inflammatory activity of ivermectin in mouse model of allergic asthma
Ivermectin significantly reduced airway inflammation, mucus hypersecretion, and airway hyperresponsiveness in a mouse model of allergic asthma. The anti-inflammatory effects were associated with inhibition of NF-κB pathway and reduction of pro-inflammatory cytokines including IL-4, IL-5, IL-13, and TNF-α.
Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice
Ivermectin significantly inhibited the production of TNF-α, IL-1β and IL-6 in LPS-stimulated macrophages. In vivo, ivermectin improved the survival of mice challenged with a lethal dose of LPS and reduced serum levels of inflammatory cytokines.
Ivermectin modulates the immune response through inhibition of NF-κB pathway
This study demonstrates that ivermectin exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway, reducing the expression of inflammatory mediators and cytokines in activated immune cells.
The anti-inflammatory effects of ivermectin in cytokine storm: A systematic review
Ivermectin has been shown to reduce inflammatory cytokine production including IL-6, IL-1β, and TNF-α through multiple mechanisms including inhibition of NF-κB and STAT3 pathways, potentially offering therapeutic benefit in cytokine storm conditions.
Antiparasitic Research
4 peer-reviewed studies
Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19
This comprehensive review by the Nobel Prize winners who discovered ivermectin details its remarkable efficacy against parasitic diseases including onchocerciasis, lymphatic filariasis, strongyloidiasis, and scabies, as well as its expanding therapeutic applications.
Ivermectin: enigmatic multifaceted "wonder" drug continues to surprise and exceed expectations
A comprehensive review of ivermectin's discovery, development, and expanding applications beyond parasitic diseases. The drug has been administered over 4 billion times with an exceptional safety profile, earning its place on the WHO List of Essential Medicines.
Ivermectin for preventing and treating COVID-19
Systematic review examining the efficacy and safety of ivermectin for prevention and treatment of COVID-19, analyzing data from multiple randomized controlled trials and observational studies.
Safety and efficacy of ivermectin for the treatment of onchocerciasis: a systematic review
Comprehensive systematic review establishing ivermectin's safety and efficacy for onchocerciasis treatment, supporting its use in mass drug administration programs across endemic regions.
Oncology & Cancer Research
4 peer-reviewed studies
Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
Ivermectin inhibited the proliferation of lung adenocarcinoma cells through induction of autophagy and apoptosis. The drug downregulated PAK1 expression and inhibited the PAK1/Akt signaling pathway, suggesting potential as an anticancer agent.
Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth
Ivermectin preferentially inhibited the viability of colorectal cancer cells with high expression of P-glycoprotein. The drug induced mitochondrial dysfunction and oxidative damage, leading to cancer cell death while showing minimal toxicity to normal cells.
Ivermectin inhibits the growth of glioma cells by inducing cell cycle arrest and apoptosis
Ivermectin significantly inhibited glioma cell proliferation by inducing G1/S phase cell cycle arrest and apoptosis. The drug downregulated cyclin D1 and CDK4 expression while activating caspase-dependent apoptotic pathways.
Ivermectin exhibits potent anticancer activity against acute myeloid leukemia
Ivermectin demonstrated significant cytotoxicity against acute myeloid leukemia cells through induction of mitochondrial dysfunction, ROS generation, and activation of apoptotic pathways, suggesting potential as a therapeutic agent for hematological malignancies.
Immunology & Immune Response
3 peer-reviewed studies
Ivermectin modulates cellular and humoral immune responses
Ivermectin enhanced cellular immunity by increasing T cell proliferation and cytokine production while modulating humoral immunity. The drug showed immunomodulatory effects that could be beneficial in various immune-related conditions.
Immunomodulatory effects of ivermectin on dendritic cells and regulatory T cells
Ivermectin modulated dendritic cell function and promoted the generation of regulatory T cells, suggesting potential therapeutic applications in autoimmune diseases and inflammatory conditions through immune regulation.
Ivermectin enhances host immunity against bacterial infections
Ivermectin enhanced innate and adaptive immune responses against bacterial pathogens, increasing phagocytic activity of macrophages and enhancing antibody production, demonstrating broad immunomodulatory properties.
Safety & Pharmacology
3 peer-reviewed studies
Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects
High doses of ivermectin (up to 10 times the approved dose) were well tolerated in healthy subjects with no serious adverse events. The study established the safety profile of ivermectin at doses higher than those typically used for parasitic infections.
A review of the safety of ivermectin
Comprehensive safety review of ivermectin based on decades of use in mass drug administration programs. Over 4 billion doses have been distributed with an excellent safety profile, confirming its status as one of the safest medications available.
Ivermectin: pharmacokinetics and metabolism in humans
Detailed review of ivermectin pharmacokinetics in humans, including absorption, distribution, metabolism, and excretion. The drug demonstrates favorable pharmacokinetic properties with good oral bioavailability and tissue distribution.
Mebendazole Research
6 peer-reviewed studies
Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature
Mebendazole, a well-known anthelmintic drug, has shown promising anticancer properties in preclinical studies. This comprehensive review examines the evidence for mebendazole as a potential anticancer agent, including its mechanisms of action involving tubulin polymerization inhibition, angiogenesis suppression, and apoptosis induction across multiple cancer types.
Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer
This study demonstrates that mebendazole significantly inhibits tumor growth and prevents lung metastasis in preclinical models of advanced thyroid cancer. The drug showed potent anti-tumor effects through disruption of microtubule dynamics and inhibition of cancer cell proliferation.
Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors
Mebendazole demonstrated significant efficacy against brain tumor models with better blood-brain barrier penetration than vincristine. The study suggests mebendazole could serve as a safer alternative to vincristine in brain tumor treatment protocols due to its favorable safety profile and CNS penetration.
Safety and efficacy of mebendazole in hookworm infection: A systematic review and meta-analysis
Comprehensive systematic review and meta-analysis evaluating mebendazole efficacy against hookworm infections. The analysis confirms mebendazole as a safe and effective treatment option with cure rates varying by species and dosing regimen, supporting its continued use in mass drug administration programs.
Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma
Case report documenting long-term disease control in a patient with metastatic adrenocortical carcinoma treated with mebendazole monotherapy. The patient achieved stable disease for over 19 months, demonstrating the potential of mebendazole as an anticancer agent with minimal toxicity.
Anthelmintic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin
This study reveals that benzimidazole anthelmintics including mebendazole activate hypoxia-inducible factor (HIF) pathways and provide neuroprotection against oxidative stress. The findings suggest potential applications in neurodegenerative diseases beyond traditional antiparasitic uses.
Research Databases
Access additional research through these trusted scientific databases:
Get Pharmaceutical-Grade Ivermectin
Access quality Ivermectin through our trusted partner JASE Medical — LegitScript certified U.S. pharmacy with physician consultation included.
Shop JASE Medical →